

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 55. (Canceled)

56. (Currently Amended) An isolated antibody or an antigen binding fragment thereof specific for a caspase-14 polypeptide, wherein said polypeptide comprises a ~~polypeptide sequence having greater than 80% identity with SEQ ID NO:2~~ or a fragment thereof.

57. (Previously Presented) The antibody of claim 56, wherein said antibody is a polyclonal antibody.

58. (Previously Presented) The antibody of claim 56, wherein said antibody is a monoclonal antibody.

59. (Previously Presented) The antibody of claim 56, wherein said antigen binding fragment comprises an Fv portion of an antibody.

60. (Previously Presented) An isolated cell expressing the antibody of claim 56.

61. (Currently Amended) An isolated antibody or an antigen binding fragment thereof specific for a caspase-14 polypeptide, wherein said polypeptide comprises a ~~polypeptide sequence having greater than 80% identity with SEQ ID NO:5~~ or a fragment thereof.

62. (Previously Presented) The antibody of claim 61, wherein said antibody is a polyclonal antibody.

C2
63. (Previously Presented) The antibody of claim 61, wherein said antibody is a monoclonal antibody.

64. (Previously Presented) The antibody of claim 61, wherein said antigen binding fragment comprises an Fv portion of an antibody.
